A c c e p t e d M a n u s c r i p t 1  There is a concern that HCV treatment may increase injecting risk behaviours  HCV treated and untreated participants were followed for a median of 1.8 years  Association between HCV treatment and injecting risk behaviours was assessed  HCV treatment was not associated with injecting drug use or used needle and syringe borrowing  HCV treatment was associated with decreased ancillary injecting equipment sharing
INTRODUCTION
The prevalence of hepatitis C virus (HCV) infection is high among people who inject drugs (PWID), ranging from 64 to 94%, globally (1, 2) . HCV infection is a major cause of morbidity and mortality among PWID (3, 4) . Interferon-based HCV treatment is safe and effective among people with a history of injecting drug use (5, 6) and those who actively inject drugs (7) .
International guidelines now recommend HCV treatment for PWID (8) (9) (10) . However, HCV treatment uptake remains suboptimal among PWID (11) (12) (13) (14) (15) , due to several barriers at the levels of system, providers and patients (4, 16, 17) . Concerns of ongoing drug use or relapse to drug use during interferon-based antiviral therapy among practitioners have contributed to low HCV treatment uptake in this population (16).
A recent meta-analysis among people with a history of injecting drug use has demonstrated similar rates of treatment success, compared to responses obtained in registration trials in the general population (6) . Similarly, a recent systematic review among people who reported active drug use has shown acceptable HCV treatment outcomes, high treatment adherence and low treatment discontinuation in this population (7) . Earlier studies have shown that HCV treatment is safe among people receiving opioid substitution treatment (OST) and does not increase drug use (18) (19) (20) . However, recent data on drug use behaviours following initiation of HCV treatment among PWID is scarce. The availability of interferon (IFN)-free direct acting antiviral (DAA) therapies (21, 22) will likely lead to an expansion of treatment among PWID. As such, a better understanding of the impact of HCV treatment on drug use and injecting behaviour is needed to inform clinical decision making in this area. This is particularly important because some clinicians often withhold therapy from PWID, given unfounded concerns that the side effects of Page 6 of 33 A c c e p t e d M a n u s c r i p t 6 interferon-based HCV treatment may mimic opioid withdrawal or lead to depression, thereby leading to a relapse to injecting drug use or increase injecting risk behaviours (23) .
The Australian Trial in Acute Hepatitis C (ATAHC) was designed to investigate treatment for recent HCV infection, predominantly in those with injecting drug use-acquired infection. The aim of this study was to evaluate recent injecting risk behaviours during follow-up among people with a history of injecting drug use and recent HCV infection enrolled in the ATAHC study that did and did not receive HCV treatment.
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METHODS

Design, setting and participants
ATAHC was a multicentre, prospective cohort study of the natural history and treatment of recent HCV infection, as previously described (24) Inclusion criteria for the study required recent HCV infection (acute or early chronic HCV infection), defined as first positive anti-HCV antibody within 6 months of enrolment and either acute clinical hepatitis C infection or asymptomatic hepatitis C infection with seroconversion (24) . Heavy alcohol intake and active drug use were not exclusion criteria. Participants with a history of injecting drug use formed the study population for this specific analysis.
All participants with detectable HCV RNA were assessed for HCV treatment eligibility and subsequent HCV-related care and treatment provided at the site of study recruitment. From enrolment, participants were followed for up to 12 weeks to allow for spontaneous HCV clearance and if HCV RNA remained detectable were offered treatment (24) . All treated and untreated participants had study visits at enrolment and every 12 weeks for up to 144 weeks (unless lost to follow-up).
All study participants provided written informed consent. The study protocol was approved by St Vincent's Hospital, Sydney Human Research Ethics Committee as well as through local ethics M a n u s c r i p t 8 committees at all study sites. The study was registered with clinicaltrials.gov registry (NCT00192569).
HCV treatment
Participants who began HCV treatment received PEG-IFN -α2a 180 micrograms weekly for 24
weeks. Due to non-response at week 12 in the initial two participants with HCV/HIV coinfection, the study protocol was amended to provide PEG-IFN and ribavirin combination therapy for 24 weeks in HIV positive individuals. Ribavirin was prescribed at a dose of 1000-1200 mg for those with genotype 1 infection and 800 mg in those with genotype 2/3.
Study measurements
Behavioural surveys were administered to all participants at enrolment and every 12 weeks during the first year and every 24 weeks during second and third years. The behavioural survey included sections on demographics (age, sex, ethnicity, education, main source of income and accommodation), history of opioid substitution treatment (including methadone and buprenorphine), injecting drug use, and injecting drug use behaviours. At enrolment, injecting drug use history was collected for lifetime, previous six months and the previous month (recent).
Recent (previous month) associated risk behaviours including use of a new sterile needle/syringe for all injections, needle/syringe borrowing and lending, and ancillary injecting equipment sharing (including mixing container, filter and water) were also collected. Follow-up information on injecting drug use and associated risk behaviours in the previous month were used for subsequent longitudinal analyses. Social functioning was measured using the shortened Social Functioning Scale of the Opiate Treatment Index (OTI) (25, 26) . M a n u s c r i p t 9
Study outcomes
The primary aim of this analysis from the ATAHC study was to evaluate the impact of HCV treatment on recent (past month) injecting risk behaviour outcomes, measured longitudinally.
The injecting risk behaviour outcomes included: 1) injecting drug use; 2) used needle and syringe borrowing; and 3) ancillary injecting equipment sharing. The study population for this aim included all participants with a history of injecting drug use at enrolment. Injecting risk behaviour outcomes from all study visits during follow-up (i.e. all visits after enrolment) were included for analysis.
Given that some participants were lost to follow-up, a secondary aim of this analysis was to evaluate changes in recent injecting risk behaviours among treated and untreated participants with recent injecting drug use at study enrolment who remained in follow-up (indicative of maintained engagement in the study). The injecting risk behaviour outcomes for this aim included: 1) used needle and syringe borrowing; and 2) ancillary injecting equipment sharing.
The study population for this analysis included all participants with injecting drug use in the previous month at enrolment and remained in follow-up >24 weeks following study enrolment (i.e. for treated individuals, this included end of treatment and/or >24 week follow-up visits).
Statistical analyses
Categorical variables were summarized using frequency and percentage. Continuous variables were summarized using mean and standard deviation (SD) or median and inter-quartile range (IQR) as appropriate. The proportion of individuals engaging in injecting risk behaviours during follow-up were assessed among treated and untreated individuals. However, to take into account A c c e p t e d M a n u s c r i p t 10 lost to follow-up and adjust for known or suspected confounders of each outcome of interest, additional analyses of the impact of HCV treatment on injecting risk behaviours during followup were also assessed using generalized estimating equations (GEE). Injecting risk behaviours were modelled as binary outcome variables. Potential factors hypothesised to be associated with recent injecting risk behaviours during follow-up were determined a priori based on factors previously shown to be associated with injecting risk behaviours or injecting drug use cessation.
These factors included age (27, 28) , gender (29, 30) , owned/renal accommodation (28, (31) (32) (33) , level of education (34), full-time or part-time employment (31, 32, 35) , OST (36) , social support (32) and injecting risk behaviour at enrolment (28, 31, 37, 38) .
Unadjusted and adjusted GEE models were specified using a binomial family function, a logit link and an autoregressive order one covariance structure, to account for the correlation of consecutive measures of injecting risk behaviours for the same participant. The effect sizes were expressed as odd ratios (ORs) or adjusted Odds Ratios (aOR). All outcome variables satisfied the assumption of linearity via Cochran-Armitage test. In addition to HCV treatment, included in all adjusted models as the primary explanatory variable of interest, other variables significant at the 0.20 level in unadjusted analyses were also initially included in the adjusted analyses. In adjusted analyses, variables were removed in a stepwise fashion using a likelihood-ratio test at each step until all factors significant at a 0.05 level remained in the model. A c c e p t e d M a n u s c r i p t 11 probability). Statistically significant differences were assessed at a 0.05 level; p-values were twosided. All analyses were performed using the Stata v12.0 (StataCorp, College Station, Texas). M a n u s c r i p t
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RESULTS
Participant characteristics
Among 163 enrolled participants (24) , 124 (76%) with a history of injecting drug use were included in this analysis. Compared to those without a history of injecting drug use (n=39), participants with a history of injecting drug use were younger, less often had full-time or parttime employment, had poorer social functioning and less often had HCV/HIV co-infection (Supplementary Table 1 ).
Among those with a history of injecting drug use (n=124), the median age was 32 years (IQR 25-39 years), the majority were male (69%) and 24% (n=30) had HCV/HIV co-infection. Overall, 82% (n=102) reported injecting drug use during the six months prior to enrolment, with methamphetamine (47%) and heroin (38%) the drugs most commonly injected (Table 1) . At enrolment, recent injecting drug use (past month) was reported by 55 (44%) participants (Table   1 ). Among these participants (n=55), 17% (n=9) had borrowed a used needle and syringe and 52% (n=28) had shared injecting equipment in the month prior to enrolment (Table 1 ).
Compared to those who did not recently inject drugs at enrolment (n=68), participants who had recently injected drugs at enrolment (n=55) more often owned or rented accommodation, more often received methadone or buprenorphine treatment and less often received HCV treatment (Supplementary Table 2 ).
HCV treatment uptake
Overall, 68% (n=84) of participants with a history of injecting drug use were treated for HCV infection. Compared to untreated participants (n=40), treated participants were more likely to Table 3) .
Participant loss to follow-up
Among those with a history of injecting drug use at enrolment (n=124), participants were followed for a median of 1. Table 4 ).
Injecting drug use during follow-up
Injecting drug use in the past 30 days among treated and untreated participants during study M a n u s c r i p t
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In unadjusted GEE analysis, recent injecting drug use during follow-up was not associated with HCV treatment (Table 2) . In adjusted analysis, recent injecting drug use during follow-up was associated with poorer social functioning [aOR 1.22, 95% CI 1.02, 1.45] and no used needle and syringe borrowing at enrolment (aOR 0.79, 95% CI 0.67, 0.93), but not HCV treatment (aOR 1.06, 95% CI 0.93, 1.21) ( Table 2 ).
Given that some people were lost to follow-up during the study, the impact of HCV treatment on cessation of injecting drug use was also assessed among people with recent injecting drug use at enrolment and who remained in >24 week follow-up (40 of 55, 73%) (Supplementary Figure 1 ).
There were no differences with respect to demographic characteristics between participants who did and did not remain in >24 week follow-up (Supplementary Table 5 ). Among the 40 participants who reported injecting drug use at enrolment and remained in >24 week follow-up, 60% (n=24) and 40% (n=16) did and did not receive treatment for HCV infection, respectively.
Among treated participants (n=24), 21% (n=5) ceased injecting drug use during >24 week follow-up. Among untreated participants (n=16), 19% (n=3) ceased injecting drug use during >24 week follow-up (Figure 2) .
Impact of HCV treatment on needle and syringe borrowing during follow-up
Needle and syringe borrowing in the past 30 days among treated and untreated participants during study follow-up were assessed (Figure 1 ). Among treated participants who had recently injected drugs, the proportion reporting recent needle and syringe borrowing was 23% (7 of 31) In unadjusted analysis, recent needle and syringe borrowing during follow-up was not associated with HCV treatment (Table 3) . In adjusted analysis, recent needle and syringe borrowing during follow-up was associated with used needle and syringe borrowing at enrolment (aOR 1.52, 95% CI 1.33, 1.75), but not HCV treatment (aOR 0.99, 95% CI 0.89, 1.07). Female gender was marginally associated with used needle and syringe borrowing (aOR 1.11, 95% CI 1.00, 1.24) ( Table 3 ).
The impact of HCV treatment on used needle and syringe borrowing was also assessed among people with recent injecting drug use at enrolment and who remained in >24 week follow-up (n=40). Among treated participants (n=24), used needle and syringe borrowing decreased from 25% (n=6) at enrolment to 8% (n=2, P=0.219) during >24 week follow-up. Among untreated participants (n=16), used needle and syringe borrowing increased from 6% (n=1) at enrolment to 19% (n=3, P=0.625) during >24 week follow-up (Figure 2) .
Impact of HCV treatment on ancillary injecting equipment sharing during follow-up
Ancillary injecting equipment sharing in the past 30 days among treated and untreated participants during study follow-up were assessed (Figure 1 (Table   4 ). Further, in adjusted analysis, ancillary injecting equipment sharing at enrolment was associated with ancillary injecting equipment sharing during follow-up (aOR 1.52, 95% CI 1.34, 1.74). Full-time or part-time employment was also marginally associated with reduced recent ancillary injecting equipment sharing during follow-up (aOR 0.86, 95% CI 0.73, 1.00) ( Table 4 ).
The impact of HCV treatment on ancillary injecting equipment sharing was also assessed among people with recent injecting drug use at enrolment and who remained in >24 week follow-up (n=40). Among treated participants (n=24), ancillary injecting equipment sharing significantly decreased from 54% (n=13) at enrolment to 17% (n=4, P=0.012) during >24 week follow-up ( Figure 2 ). Among untreated participants (n=16), ancillary injecting equipment sharing remained stable from 50% (n=8) at enrolment to 44% (n=7, P=1.000) during >24 week follow-up ( Figure   2 ).
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DISCUSSION
In this study of PWID with recently acquired HCV, interferon-based HCV treatment was not associated with an increase in injecting drug use or needle and syringe borrowing during followup. However, HCV treatment was associated with a reduction in ancillary injecting equipment sharing during follow-up. These results should address concerns by some practitioners that HCV treatment may lead to an increase in drug use risk behaviours (16, 39). Programs to enhance HCV assessment and treatment among PWID should be expanded, given that HCV treatment, does not lead to increases in injecting risk behaviours, is safe and effective among PWID and reduces HCV-related morbidity and mortality.
HCV treatment was not associated with an increase in injecting drug use or needle and syringe borrowing during follow-up. This is consistent with previous work suggesting that HCV treatment does not lead to increases in injecting drug use (18) (19) (20) . In one study of HCV treatment among people receiving OST in Australia, compared to baseline, there was no impact of HCV treatment on drug use behaviours at the end of treatment or at 24 weeks following treatment (20) . This is important because the side effects of interferon-based therapy mimic opioid withdrawal and a major concern among some clinicians is that treatment might lead to an increase in drug use or relapse to substance use (16, 39). The finding that HCV treatment did not increase needle and syringe borrowing during follow-up is novel. In fact, although it was not significant, decreases in needle and syringe borrowing during >24 week follow-up (25% to 8%) were observed among treated participants remaining in >24 week follow-up, which is in contrast to an increase observed among untreated participants remaining in >24 week follow-up (6% to 19%). In conclusion, in this study of PWID treated for recent HCV infection, HCV treatment was not associated with an increase in injecting drug use or needle and syringe borrowing during followup. However, HCV treatment was associated with a reduction in ancillary injecting equipment sharing during follow-up. There is now considerable data demonstrating that HCV treatment is safe and effective among people with a history of injecting drug use (5, 6) and those who actively inject drugs (7), and international guidelines now recommend HCV treatment for PWID (8) (9) (10) . The data in this study provide further support of the expansion of programs aimed at enhancing assessment and treatment for HCV among PWID. Treatment should not be withheld based on unfounded concerns that treatment will lead to increases in drug use or injecting equipment sharing. Further, the findings of this study illustrate the importance of incorporating harm reduction education by health care providers into HCV treatment programs and potential M a n u s c r i p t 20 benefit in reducing ancillary injecting equipment sharing. This finding has important prevention implications and may inform studies evaluating HCV treatment as prevention (4) . This is also particularly important given the potential risk for HCV reinfection following HCV treatment.
Although the reported rates of HCV reinfection to date have been low (7, 42) , continued risk reduction education will be important as interferon-free regimens are expanded to populations of PWID who might be at greater risk for re-exposure.
The impending interferon-free era will certainly be an exciting time with the potential to substantially impact on HCV-related disease burden and work towards control of HCV among PWID (4). However, further studies will be needed to evaluate the impact of HCV therapy on risk behaviours in the interferon-free era, particularly given the importance of the risk of HCV reinfection. M a n u s c r i p t
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